syn-004
Generic: ribaxamase·Code: SYN-004
syn-004: sourced relationships with 1 company · 1 clinical trial tracked.
syn-004 evidence translation
What we can confirm
1 tracked trial
What it means
Source-backed records connect syn-004 to TOVX; that link alone does not prove the drug works.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
How could syn-004 → TOVX affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Acute Graft-Versus-Host Reaction Following Bone Marrow Transplant
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| Theriva Biologics, Inc. (TOVX) Acute Graft-Versus-Host Reaction Following Bone Marrow Trans… | Phase 1/Phase 2 |
Clinical Trial Registry Records (1)
Phase 1b/2a Evaluation of the Safety and Tolerability of SYN-004 in Adult Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) Recipients
Primary endpoint: SYN-004 systemic absorption
InterventionalRandomizedtriple36 targetStarted 2021-02Completion 2030-091 site · United StatesTheriva Biologics, Inc.
Frequently asked questions
Which companies have sourced relationships with syn-004?
syn-004 has dated SEC/FDA relationship records for Theriva Biologics, Inc..
How many clinical trials involve syn-004?
BioSniper tracks 1 clinical trial involving syn-004.